From Monday, May 11 2009
To Wednesday, May 13 2009
Every day
Advances in Drugs, Devices and Diagnostics for the Brain and Nervous System
St. Regis San Francisco
May 11, 2009: Collaborating for Cures Summit
May 12 -13, 2009: The Neurotech Industry Investing and Partnering Conference
New this year! Attendee Networking Directory for confirmed participants. Contact and set up on-on-one meetings with other attendees.
The premier partnering and investing conference for the neurotechnology
industry including pharmaceuticals, medical devices and diagnostics
will be held May 12-13. The first Collaborating for Cures Summit
focused on collaboration among nonprofits and industry will be held on
May 11 also at the St. Regis in San Francisco.
The Neurotech Industry Conference is a global forum where investors,
executives, entrepreneurs, scientists and others involved in the
development of new treatments and diagnostics for the brain and nervous
system come together to shape the future of their organization and the
industry.
This market defining conference features keynotes on the state of the
neurotech industry, cutting edge company presentations, and panel
discussions on a comprehensive selection of neurotech topics.
Hear about next generation treatments for Alzheimer's, addiction,
anxiety, depression, pain, sensory disorders, obesity, stroke,
schizophrenia, sleep disorders, epilepsy, multiple sclerosis, traumatic
brain injury, spinal cord injury, Parkinson's and more.
Conference Highlights
At The Neurotech Conference you'll get a first-hand glimpse of What's in the Pipeline
- Find out about new product licensing and partnering opportunities
- Learn what venture and strategic investors are looking for
- Discover emerging technologies and companies
- Learn about cutting edge translational research and funding opportunities
- Plan networking and schedule meetings ahead of time with other attendees
Media
To request a media pass please send relevant information to zack@neurotechindustry.org.
Contact Us
Submit
speaker proposals and find out about Sponsorship opportunities.
Sponsorship identifies your company as a leading organization in the
neurotech community. NIO will work with you to create a customized
package that meets your marketing needs. zack@neurotechindustry.org
Join leading investors, executives, and
entrepreneurs involved in the development of drugs, devices and diagnostics for
the brain and nervous system.
Hear
from over 70 CEO's about next generation treatments for CNS disorders including
Alzheimer's, addiction, anxiety, depression, pain, hearing loss, obesity,
stroke, schizophrenia, sleep disorders, spinal cord injury, traumatic brain
injury, epilepsy, Parkinson's and more.
The Neurotech
Industry Investing and Partnering Conference 2009 will take place May 11-13, 2009 at the
modern St. Regis in beautiful San Francisco and is being hosted by the
Neurotechnology Industry Organization.Don't miss this excellent networking opportunity to discover partnering and investing opportunities across commercial neuroscience.
Audience: CEOs, CSOs, CFOs, business development executives, non-profit leaders, corporate investors, venture capitalists, private equity investors, institutional investors, technology transfer experts, licensing executives
Conference organized by the Neurotechnology Industry Organization (NIO) and NeuroInsights.
NIO is the trade association representing companies involved in neuroscience, brain research institutes and patient advocacy groups worldwide. Over 90 organizations have joined NIO in our first two years in an effort to accelerate the development of treatments for brain and nervous system illnesses.
Network with 70 confirmed speakers focused on commercial neuroscience
Investing in Neurotech Panel
Ellen Baron, Partner, Oxford Bioscience Partners
Andrew Jay, Managing Partner, Siemens Venture Capital
Vincent Kim, Partner, Aberdare Ventures
Matthew Perry, Portfolio Manager, Biotechnology Value Fund
Moderator: Casey Lynch, NeuroInsights
Novel Platforms for CNS Drug Discovery and Neurodevice Development
Daniel Abrams, Acting CEO, CSO/CMO, Sierra Neuropharmaceuticals
Thomas King, President and CEO, Alexza Pharmaceuticals
Paul McGonigle, Vice President External Scientific Affairs, PsychoGenics
Will Rosellini, President and CEO, MicroTransponder
Session Chair: Jeff Calcagno, Principal, Scale Venture Partners
Navigating the Global Regulatory Process - Panel Discussion
Mark Demitrack, Chief Medical Officer, Neuronetics
Suzan Onel, Partner, NIO FDA Policy Advisor, K&L Gates
Bonnie Segal, Vice President, Segal Institute for Clinical Research
Moderator: Joyce Cramer, President, Epilepsy Therapy Project
Neurodegenerative Disease: Alzheimer's and Parkinson's
Steve Orndorff, President and CEO, Accera
John Mordock, President and CEO, Neurologix
Daryl Kipke, President and CEO, NeuroNexus Technologies
Richard Hadden, President and CEO, Cytox
Session Chair: John Reher, Managing Director, Brain Trust Accelerator Fund
Neuroscience Research & Development Partnerships
Mary Chamberlain, Global External R&D, Lilly Research Labs, Eli Lilly
Carol Greve-Philips, Vice President, Corporate Development, Genzyme
Dave Schulz, Senior Director, Worldwide Business Development, Pfizer
Todd Whitehurst, Vice President Emerging Indications, Boston Scientific
Moderator: Dan O'Connell, Managing Partner, NeuroVentures Capital
Neuroregeneration and Stem Cells
Deborah Eppstein, President and CEO, Q Therapeutics
Andres Haegerstrand, Chief Scientific Officer, NeuroNova
Jonathan Kil, President and CEO, Sound Pharmaceuticals
Martin McGlynn, President and CEO, StemCells, Inc.
Session Chair: Frank Eeckman, NeuroInsights, NIO
Partnering and Licensing in Neurotech Panel
Lothar Krinke, Vice President, Research and Bus. Dev., Medtronic Neuromodulation
David Paterson, Vice President, Business Development, Impax Pharmaceuticals
Shafique Virani, Director, Global Business Development, Roche
Yael Weiss, Director, Licensing and External Research, Merck
Session Chair: Christine de los Reyes, Managing Director, BioPartnering Solutions
NeuroVaccines: The Use of Vaccines in Neurology and Psychiatry
Raafat Fahim, President and CEO, Nabi
Mark Schwartz, President and CEO, Bayhill Therapeutics
Daniel Chain, CEO, Intellect Neurosciences
Session Chair: Roger Quy, General Partner, Technology Partners
Traumatic Injury: Stroke, Traumatic Brain Injury, and Spinal Cord Injury
Martin Dieck, President and CEO, Nfocus Neuromedical
Shawn Lunney, CEO, Neurolutions
Vincent Simmon, President and CEO, Xytis
Michael Singer, CEO, BrainScope
Session Chair: Teo Forcht Dagi, Partner, HLM Venture Partners
Neuroscience Translation, Tech Transfer and Collaboration Opportunities
Jamie Driscoll, Chief of Research Services, NIMH
Jill Heemskerk, Acting Director, Office of Translational Research, NINDS
Joe Pancrazio, Program Director, Extramural, Repair & Plasticity Cluster, NINDS
Session Chair: Melissa Maderia, Technology Transfer Specialist,NINDS
Novel Platforms in Neurodevice Development
Frank Fischer, President and CEO, Neuropace
Ben Matteo, President and CEO, Eos Neuroscience
Andrew Thompson, CEO, Proteus Biomedical
Jamie Tyler, President and CEO, SynSonix
Session Chair: Kevin Wasserstein, Managing Director, Versant Ventures
Next Generation Neuropsychiatry
Barry Brand*, CEO, CeNeRx
Ian Massey*, President and CEO, Synosia
Dan Segal, President North America, Brain Resource Company
Neal Simon, President and CEO, Azevan
Session Chair: Manuel Lopez-Figueroa,Vice President, Bay City Capital
Collaborative Research Infrastructure
John Wilbanks, Vice President, Science Commons, NeuroCommons
June Kinoshita, Executive Editor, Alzheimer Research Forum and SWAN
Michael Rogan, Associate Director, pd Online Research, Michael J. Fox Foundation
Jay "Marty" Tenenbaum, Chairman and Chief Scientist, CollabRx
Moderator: Lesa Mitchell, Vice President, Ewing Marion Kauffman Foundation
New Models of Funding
Howard Fillit, Executive Director, Alzheimer's Drug Discovery Foundation
Melanie Leitner, COO, Prize4Life
Sharon Hesterlee, SVP and Executive Director, MDA Venture Philanthropy
Chris Gibbons, Executive Director, CureNeuro
Moderator: Greg Simon, President, FasterCures
Leveraging Corporate Partnerships
Robert Pacifici, Chief Scientific Advisor, CHDI, Inc.
Paul McGonigle, Vice President External Scientific Affairs, PsychoGenics
Robert W. Mahley, President, The J. David Gladstone Institutes
Guy Seabrook, Franchise Lead Neuroscience & Ophth, External Research, Merck
Moderator: Casey Lynch, NeuroInsights
Collaborative Strategies for Cures
Zaven Khachaturian, President and CEO, Lou Ruvo Brain Institute
Rusty Bromley, Chief Operating Officer, Myelin Repair Foundation
Cynthia Joyce, Executive Director, SMA Foundation
Moderator: Marcia Kean, Founder & Managing Director, Feinstein Kean Healthcare
Register now for The Neurotech Industry Investing and Partnering Conference 2009
Location
The St. Regis | 125 3rd St. | San Francisco, CA | 94103
